Trial Profile
An Open-Label Study to Assess the Efficacy and Tolerability of Repeated Doses of DX-88 (Recombinant Plasma Kallikrein Inhibitor) in Patients With Hereditary Angioedema
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 19 May 2021
Price :
$35
*
At a glance
- Drugs Ecallantide (Primary) ; Ecallantide (Primary)
- Indications Hereditary angioedema
- Focus Therapeutic Use
- Acronyms EDEMA2
- Sponsors Dyax
- 05 Jun 2014 New trial record